| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73fbc44d96349c8b0dabbb7580d4b428 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6d56fcf675c999fdb45ec4c494a975c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c136d449ff75282afeb071ee872615d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fd586f34cff67a6f23bab85c9a14ddf |
| publicationDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021056610-A1 |
| titleOfInvention |
High affinity antibodies to cd39 and uses thereof |
| abstract |
High-affinity antibodies recognizing CD39 are disclosed. The antibodies are capable of neutralizing ATPase activity of CD39 on CD-39 expressing cells. Such antibodies are useful for treatment of cancers and other disorders mediated by CD39 activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345757-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023182530-A1 |
| priorityDate |
2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |